Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

Pegilodecakin alone or in combination for heavily pre-treated advanced kidney cancer patients

This study looked at the use of pegilodecakin alone or in combination with immunotherapy or targeted therapy for the treatment of people with advanced solid tumours. Pegilodecakin is a form of cytokine called interleukin-10. The interleukin-10 is attached to a substance called polyethylene glycol (PEG) to improve how the drug works to unleash the immune […]

read more

Immune checkpoint inhibitors for sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the tumour cells look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to targeted […]

read more

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]

read more

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The European Commission will now review the CHMP recommendation and make a final decision in the next few months […]

read more

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

read more

Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

The microbes in the gut (the gut microbiome) are a key part of our immune system. The use of antibiotics disrupts the gut microbiome and has been shown to make people susceptible to various illnesses. In this study, researchers investigated how antibiotics may influence response to treatment and clinical outcomes in people with metastatic renal […]

read more

Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy

This study compared disease outcomes, treatments, and dose reductions in patients undergoing first-line treatment with targeted therapy or immune checkpoint inhibitor therapy (immunotherapy) for metastatic renal cell carcinoma (RCC) according to age. Patients aged ≥75 years had a longer time from diagnosis to start of treatment with targeted therapy than those aged <65 years and […]

read more

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This […]

read more

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]

read more
Showing 1 to 10 of 47 results
  TOP